Cardiovascular devices are used in treating diseases related to the heart and the circulatory system. Cardiac Rhythm Management (CRM) devices are those devices which are used to restore the natural synchronized pumping rhythm of the heart. Cardiac Resynchronization Therapy (CRT) is a device used for the treatment of heart failure-induced conduction disturbances and ventricular dyssynchrony. GlobalData uses proprietary data and analytics to provide a comprehensive report on the cardiac resynchronisation therapy market in Portugal. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the cardiac resynchronisation therapy market in Portugal was Abbott Laboratories followed by Biotronik SE & Co, Boston Scientific, EBR Systems, Medtronic and MicroPort Scientific.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction. Cardiac Resynchronization Therapy – Defibrillator uses an Implantable Cardioverter Defibrillator (ICD) to improve the coordination of the heart rhythm. Cardiac Resynchronization Therapy – Pacemaker uses a pacemaker device to improve the coordination of the heart rhythm. Wireless – Cardiac resynchronization therapy uses a leadless pacing device along with the conventional Implantable Cardioverter Defibrillator (ICD) and/or Pacemaker to improve the coordination of the heart rhythm.
The cardiac resynchronisation therapy market in Portugal can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size cardiac resynchronisation therapy in Portugal, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
